TVRDTVARDI THERAPEUTICS, INC.
Is Tvardi Therapeutics struggling financially?
Yes, by its own account. Tvardi Therapeutics told the SEC on 8 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $24.8M
- Source filing
- 10-Q 8 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
3months
If the burn speeds up
Empty by Sep 2026
-
5months
If it eases off
Empty by Nov 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$15.8M
÷
Cash burned over the last 12 months
$44.4M
What Tvardi Therapeutics told the SEC
…as of the date that these condensed consolidated financial statements are issued and concluded that there are conditions present in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern. To date, the Company has no products approved for marketing and sale and it has not yet recorded any revenue from product sales. The Company’s ability to achieve profitability is…
TVARDI THERAPEUTICS, INC., Form 10-Q, filed 8 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 72.9% share-count increase The company issued stock. Each share now owns 42.2% less of the business than a year ago, before any change in the price.
- Cash burn is increasing It is spending 12% more cash per year than it was, so the runway above shortens even if nothing else changes.
Other Biotech/Pharma companies that filed the doubt
- DWTX Dogwood Therapeutics $84.6M
- IMDX Insight Molecular Diagnostics $142.0M
- LNAI Lunai Bioworks $9.8M
- NUWE Nuwellis $4.2M
- PASG Passage BIO $14.3M
- HOWL Werewolf Therapeutics $42.5M